Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11252528 | 0.91 | GAA (0.70) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL2705170 | 0.81 | GAA (0.59) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL11142878 | 0.81 | GAA (0.59) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL10498902 | 0.81 | GAA (0.59) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL6093032 | 0.81 | GAA (0.59) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL6161907 | 0.81 | THRB (0.66) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL6554127 | 0.80 | GAA (0.58) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL141474 | 0.80 | GAA (0.58) | GAAALDH1A1HTTTHRBMAPT | |
| SCHEMBL196987 | 0.80 | CA2 (0.46) | GAAALDH1A1HTTMAPTRPS6KA2 | |
| SCHEMBL6572219 | 0.79 | GAA (0.58) | GAAALDH1A1HTTTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450358-A1 | Fused, tricyclic sulfonamide inhibitors of gamma secretase | Elan Pharmaceuticals Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021056-A1 | Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | GAA 46/4885ALDH1A1 1779/4885HTT 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.